Bristol Myers Squibb's (BMY) new schizophrenia drug, Cobenfy, improves symptoms with a well-tolerated safety profile in two ...

Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bristol-Myers Squibb (BMY – Research Report) and Envista ...

By Michael Erman (Reuters) -Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing ...

BofA raised the firm’s price target on Bristol Myers (BMY) to $60 from $55 and keeps a Neutral rating on the shares. Bristol reported ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

The biopharmaceutical company posted revenue of $11.89 billion in the period, also exceeding Street forecasts. Nine analysts surveyed by Zacks expected $11.32 billion. Bristol Myers expects full-year ...

Bristol-Myers Squibb Co.’s stock rose 2.9% early Thursday, after the drug company posted better-than-expected third-quarter earnings and raised its guidance. Princeton, N.J.-based Bristol Myers ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Coventry Police Department said a dog owner requested that their dog be killed because it had an aggressive temperament. It happened on Oct. 24. Investigators arrested Anthony Demitraszek as a ...

Bristol Myers Squibb posted better-than-expected third-quarter earnings on Thursday citing strong sales of established drugs ...

PRINCETON, N.J. — PRINCETON, N.J. — Bristol Myers Squibb Co. (BMY) on Thursday reported third-quarter profit of $1.21 billion. On a per-share basis, the Princeton, New Jersey-based company ...